HCM - Hutchmed completes enrollment in phase 3 trial of blood disorder drug
- Hutchmed (China) ( NASDAQ: HCM ) said it completed patient enrollment in a phase 3 trial of sovleplenib to treat adult patients with primary immune thrombocytopenia (ITP) in China.
- The study called ESLIM-01, which started in October 2021, has enrolled 188 patients and is evaluating sovleplenib versus placebo to treat adult patients with ITP — a disorder which can cause excessive bruising and bleeding as the blood does not clot as it should due to low levels of platelets.
- The main goal of the study is the durable response rate. Secondary and exploratory goals include overall response rate, incidence of treatment emergent adverse events, and patient quality of life improvement.
- Results from the trial are expected to be reported in H2 2023 and, if positive, Hutchmed plans to seek approval of the drug in China.
For further details see:
Hutchmed completes enrollment in phase 3 trial of blood disorder drug